Soleno Therapeutics

Soleno Therapeutics faces securities litigation alleging undisclosed DCCR safety risks during March-November 2025. Lead plaintiff deadline: May 5, 2026.

Rosen Law Firm filed securities class action against Trip.com over alleged false statements on regulatory risks. Investors have until May 11, 2026 to become lead plaintiffs.

Portnoy Law Firm launches class action against $SLNO for allegedly concealing safety issues with lead drug DCCR, citing 27% stock plunge following patient death disclosure.

Law firm files class action against $ENPH for allegedly overstating inventory management and financial prospects during 2025.

Rosen Law Firm alerts $SLNO investors about class action lawsuit alleging false statements regarding DCCR drug safety. Lead plaintiff deadline: May 5, 2026.

Pomerantz LLP sues Soleno Therapeutics ($SLNO) over alleged securities fraud as stock plummets 39% following DCCR safety concerns and patient death disclosure. Lead Plaintiff deadline: May 5, 2026.

Rosen Law Firm files class action against $IBRX, alleging founder Patrick Soon-Shiong overstated Anktiva capabilities, misleading investors about company prospects.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.

Rosen Law Firm files securities class action against $SLNO for alleged misstatements regarding safety concerns with DCCR drug candidate for Prader-Willi syndrome treatment.

Schall Law Firm filed securities fraud class action against $SLNO for allegedly concealing safety concerns in Phase 3 DCCR trial. Investors eligible through November 4, 2025.

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.